Medidata Solutions Inc (MDSO) Stake Lessened by Lord Abbett & CO. LLC

Share on StockTwits

Lord Abbett & CO. LLC cut its stake in shares of Medidata Solutions Inc (NASDAQ:MDSO) by 12.5% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 293,726 shares of the company’s stock after selling 41,992 shares during the period. Lord Abbett & CO. LLC owned approximately 0.48% of Medidata Solutions worth $19,803,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. raised its position in shares of Medidata Solutions by 127.2% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 945 shares of the company’s stock worth $64,000 after purchasing an additional 529 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of Medidata Solutions during the fourth quarter worth $90,000. Whittier Trust Co. of Nevada Inc. raised its position in shares of Medidata Solutions by 1,068.0% during the fourth quarter. Whittier Trust Co. of Nevada Inc. now owns 2,558 shares of the company’s stock worth $172,000 after purchasing an additional 2,339 shares during the period. Advisor Group Inc. raised its position in shares of Medidata Solutions by 27.1% during the fourth quarter. Advisor Group Inc. now owns 2,553 shares of the company’s stock worth $173,000 after purchasing an additional 545 shares during the period. Finally, Stephens Inc. AR raised its position in shares of Medidata Solutions by 8.7% during the fourth quarter. Stephens Inc. AR now owns 2,722 shares of the company’s stock worth $184,000 after purchasing an additional 218 shares during the period.

In related news, EVP Daniel Patrick Shannon sold 19,725 shares of the business’s stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $75.17, for a total transaction of $1,482,728.25. Following the completion of the transaction, the executive vice president now owns 70,497 shares of the company’s stock, valued at approximately $5,299,259.49. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Rouven Bergmann sold 12,512 shares of the business’s stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $75.00, for a total value of $938,400.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 49,357 shares of company stock valued at $3,705,792. 4.70% of the stock is currently owned by corporate insiders.

Shares of NASDAQ MDSO opened at $76.21 on Monday. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.14. Medidata Solutions Inc has a one year low of $60.10 and a one year high of $88.87. The stock has a market capitalization of $4.75 billion, a price-to-earnings ratio of 79.39, a PEG ratio of 5.10 and a beta of 1.36.

Medidata Solutions (NASDAQ:MDSO) last released its quarterly earnings results on Tuesday, February 12th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.08. The company had revenue of $167.19 million during the quarter, compared to the consensus estimate of $168.08 million. Medidata Solutions had a return on equity of 10.03% and a net margin of 8.17%. The firm’s revenue was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.41 EPS. On average, equities research analysts anticipate that Medidata Solutions Inc will post 0.8 EPS for the current fiscal year.

A number of research analysts have recently weighed in on the company. Leerink Swann assumed coverage on Medidata Solutions in a report on Wednesday, January 2nd. They set a “market perform” rating and a $70.00 price target on the stock. Zacks Investment Research downgraded Medidata Solutions from a “buy” rating to a “hold” rating in a report on Monday, January 28th. Piper Jaffray Companies lowered their price target on Medidata Solutions to $83.00 and set an “overweight” rating on the stock in a report on Friday, January 4th. JPMorgan Chase & Co. downgraded Medidata Solutions from a “neutral” rating to an “underweight” rating in a report on Thursday, December 13th. Finally, TheStreet downgraded Medidata Solutions from a “b” rating to a “c+” rating in a report on Thursday, December 20th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and seven have assigned a buy rating to the company’s stock. Medidata Solutions currently has an average rating of “Hold” and an average target price of $83.64.

ILLEGAL ACTIVITY WARNING: “Medidata Solutions Inc (MDSO) Stake Lessened by Lord Abbett & CO. LLC” was first reported by Week Herald and is owned by of Week Herald. If you are accessing this report on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The legal version of this report can be viewed at https://weekherald.com/2019/03/18/medidata-solutions-inc-mdso-stake-lessened-by-lord-abbett-co-llc.html.

Medidata Solutions Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Featured Story: Call Option

Want to see what other hedge funds are holding MDSO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medidata Solutions Inc (NASDAQ:MDSO).

Institutional Ownership by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.